Servatus raises $7.5 million to advance autoimmune therapies with its microbial biotherapeutics clinical programs
Servatus has raised $7.5 million in an oversubscribed capital raise, with strong support from sophisticated shareholders Funds raised will underpin Servatus' live microbial and engineered protein biotherapeutics drug development Two Phase 1/2 clinical trials to launch shortly in Queensland, for insomnia and rheumatoid arthritis, complementing existing trials on-foot in inflammatory bowel disease (IBD), H. pylori infection...
Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China
The approval marks the first locally-discovered and approved SARS-CoV-2 target-specific treatment in China, through a randomized, double-blind and placebo-controlled trial Brii Bio is also seeking U.S. FDA Emergency Use Authorization for the amubarvimab/romlusevimab combination DURHAM, N.C. and BEIJING, Dec. 9, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK)...
Pexip Applauded by Frost & Sullivan for Improving the Accessibility and Delivery of Healthcare Services with Its Video Conferencing Platform
Pexip's video conferencing platform enables patients to obtain telehealth services regardless of their location or device choice or version. SAN ANTONIO, Dec. 9, 2021 /PRNewswire/ -- Frost & Sullivan recently assessed video conferencing services in the Australian healthcare industry and, based on its findings, recognizes Pexip with the 2021 Australian Competitive Strategy Leadership Award for its video conferencing services in...
Challenges Facing the Saudi Labor Market Due to COVID-19 Reviewed in a Forum Held in Riyadh
RIYADH, Saudi Arabia, Dec. 9, 2021 /PRNewswire/ -- The Social Dialogue Forum's eleventh version, titled "Labor Market in the Light of Corona Pandemic - Effects and Solutions", was launched today in Saudi capital of Riyadh, and was attended by His Excellency the Minister of Human Resources and Social Development in Saudi Arabia, Eng. Ahmed bin Sulaiman Al-Rajhi. The Forum brings together...
Novalis LifeSciences Launches its Second Life Science Investment Fund with $300M and announces key new team members.
HAMPTON, N.H., Dec. 9, 2021 /PRNewswire/ -- Novalis LifeSciences LLC, an investment and advisory firm for the Life Science industry, announced today that is has raised $300M in capital for its second fund – Novalis LifeSciences Investments II, LP. In addition, Paul M. Meister has joined the firm as partner. Novalis LifeSciences...
Enerjoy Launches Upgraded ShutEye 2.0 App to Provide Deeper Sleep Analysis
HONG KONG, Dec. 8, 2021 /PRNewswire/ -- Leading mobile sleep tracking application ShutEye has recently been upgraded to version 2.0. Developed by Enerjoy Limited, the application assists users in understanding their sleep quality and patterns by providing a comprehensive analysis of each night's rest. The upgrade will be available from December 20th, and will be complete with more functionality, a...
CRI Online: China’s Fangchenggang City Hosts 2021 IMICF
FANGCHENGGANG, China, Dec. 8, 2021 /PRNewswire/ -- A news reported by CRI Online: On December 6, the 2021 International Medical Innovation Cooperation Forum was held in Fangchenggang City, Guangxi Province online and offline. The scene of the 2021 International Medical Innovation Cooperation Forum This forum will play an important role in promoting the high-quality development of...
Donisi Health Takes Home First Place in the Prestigious Innovations in Cardiovascular Intervention Competition
MedTech Startup Focused on Home Monitoring for Patients with Congestive Heart Failure and Other Chronic Diseases Wins the 2021 ICI Pitch Competition and $200,000 Award TEL AVIV, Israel, Dec. 8, 2021 /PRNewswire/ -- Donisi Health (Donisi) prevailed in this year's ICI Innovation Competition – the premier international conference for innovations in cardiovascular intervention. Competing against startups from all over the...
I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer’s Disease
SHANGHAI and GAITHERSBURG, Md., Dec. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient had been dosed in the I-Mab and Nhwa-sponsored U.S. Phase I study of Protollin, an investigational drug being co-developed to treat Alzheimer's disease....
Treadwell Therapeutics Announces A Presentation at the 2021 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor
NEW YORK and HONG KONG, Dec. 8, 2021 /PRNewswire/ -- Treadwell Therapeutics, today announced a presentation for the Company's CFI-402257 program, an oral, best-in-class TTK inhibitor, at the 2021 San Antonio Breast Cancer Symposium (SABCS) being held from December 7-10, 2021. This presentation will describe dose escalation and expansion data from CFI-402257-CL-001, an investigator-initiated study of CFI-402257 in advanced solid tumors. "The anti-tumor...
